Consolidated Investment Analysis for Quest Diagnostics Company Description
Quest Diagnostics Incorporated is a provider of diagnostic testing, information and services. It offers diagnostic testing services and products to patients, physicians, payers, and others. It offers the United States patients and physicians the access to diagnostic testing services through its nationwide network of laboratories and Company owned patient service centers. It is a provider of clinical testing, including gene-based and esoteric testing, anatomic pathology services and testing for drugs-of-abuse, and the provider of risk assessment services for the life insurance industry. It also is a provider of testing for clinical trials. Its diagnostics products business manufactures and markets diagnostic test kits and point-of-care testing. It provides testing services to a range of customers. In April 2011, it acquired Athena Diagnostics. In May 2011, it acquired Celera Corporation. Share Statistics Symbol Current Price 52wk Range Avg Vol (3m)
DGX 58.00 43.38 – 61.21 1,587,910
EPS Market Cap 52wk Change P/E (ttm)
2.92 9.13M 14.62% 19.88
Financial Summary
On April 20, 2011, Quest Diagnostics Inc reported 1st quarter 2011 earnings of 1.00 per share. This result was in line with the consensus of the 21 analysts following the company and exceeded last year's 1st quarter results by 12.36%. The next earnings announcement is expected on July 20, 2011. Quest Diagnostics Inc reported annual 2010 earnings of 4.05 per share on January 25, 2011. DGX had 1st quarter 2011 revenues of 1.82bn. This bettered the 1.81bn consensus of the 19 analysts covering the company. This was -0.13% below the prior year's 1st quarter results. DGX had revenues for the full year 2010 of 7.37bn. This was -1.16% below the prior year's results.
Analyst Consensus Buy
Outperform
Hold
Underperform
Sell
No Opinion
This is the consensus forecast amongst 22 polled investment analysts. Analyst Detail
Buy
Outperform
Hold
Underperform
Sell
No Opinion
Latest
2
6
13
1
0
0
4 weeks ago
2
6
11
1
0
0
2 months ago
3
6
11
1
0
0
3 months ago
3
6
11
1
0
0
Last year
3
4
10
2
0
0
The 17 analysts offering 12 month price targets for Quest Diagnostics Inc (DGX:NYQ) have a median target of 64.00, with a high estimate of 70.00 and a low estimate of 50.00. The median estimate represents a 9.66% increase from the last price of 58.36. Technical Analysis Chart
Report Disclaimer DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing. This report is a service of Seo Freisin, Inc., a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate
all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. ChartPoppers.com is a Web site wholly-owned by Seo Freisin, Inc. Seo Freisin, Inc., has not been compensated for any of the Companies mentioned in this report, we also do not own any shares in the companies discussed in this report. Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http:// www.finra.org